Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth Hopes
TLDR CELC stock fell 0.49% to $65.25, then dipped another 1.39% after hours to $64.34. Gedatolisib triplet delivers 21.5 months…
Market coverage 1 stories
TLDR CELC stock fell 0.49% to $65.25, then dipped another 1.39% after hours to $64.34. Gedatolisib triplet delivers 21.5 months…